Walgreens Boots Alliance, Inc.

WBA

US9314271084

Drug Retailers

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-05 EDT			5-day change	1st Jan Change
11.26 ^USD	+1.44%		-6.90%	-56.87%

07-03	Top Decliners	MT
07-03	UBS Adjusts Price Target on Walgreens Boots Alliance to $12 From $17, Maintains Neutral Rating	MT

Walgreens Boots Alliance Revises Earnings Guidance for the Full Year of Fiscal 2017

January 30, 2017 at 03:06 pm

Walgreens Boots Alliance revised earnings guidance for the full year of fiscal 2017. The company now revised its guidance for fiscal-year 2017, and now anticipates adjusted net earnings per share of $4.90 to $5.08.

Latest news about Walgreens Boots Alliance, Inc.

Top Decliners	07-03	MT
UBS Adjusts Price Target on Walgreens Boots Alliance to $12 From $17, Maintains Neutral Rating	07-03	MT
Sector Update: Health Care Stocks Softer Late Afternoon	07-02	MT
Sector Update: Health Care Stocks Retreat Tuesday Afternoon	07-02	MT
Sector Update: Health Care	07-02	MT
Walgreens Facing Persistent Retail, Pharmacy Headwinds, RBC Says	07-02	MT
You can't escape politics	07-02
RBC Cuts Price Target on Walgreens Boots Alliance to $13 From $22, Keeps Sector Perform Rating	07-02	MT
ANALYST RECOMMENDATIONS : Adobe, Nike, Solaredge, Welltower, Spectris...	07-02
Nasdaq Closes at Record High as Markets Evaluate Manufacturing Data	07-01	MT
Nasdaq Closes at Record High as Markets Evaluate Manufacturing Sector Data	07-01	MT
Sector Update: Health Care Stocks Retreat Late Afternoon	07-01	MT
US Equities Markets End Higher Monday as Investors Parse Manufacturing Sector Data	07-01	MT
Sector Update: Health Care	07-01	MT
Equity Markets Rise Intraday as Traders Analyze Manufacturing Sector Data	07-01	MT
Correction: Top Midday Stories: Boeing to Acquire Spirit AeroSystems; Robinhood Acquires Pluto; FTC Probes Teva; BlackRock Acquires Preqin; SCOTUS Grants Trump Some Immunity	07-01	MT
Correction: Market Chatter: Walgreens Boots Alliance's Boots Unit Sees Top Executive Step Down	07-01	MT
Top Midday Stories: Boeing to Acquire Spirit AeroSystems; Robinhood Acquires Pluto; FTC Probes Teva; BlackRock Acquires Preqin; SCOTUS Grants Trump Some Immunity	07-01	MT
BofA Securities Cuts Price Target on Walgreens Boots Alliance to $11 From $12, Maintains Underperform Rating	07-01	MT
Walgreens Boots Alliance Chief Executive to Resign	07-01	MT
TD Cowen Adjusts Price Target on Walgreens Boots Alliance to $22 From $35, Maintains Buy Rating	07-01	MT
JPMorgan Adjusts Price Target on Walgreens Boots Alliance to $20 From $30, Maintains Overweight Rating	07-01	MT
ANALYST RECOMMENDATIONS : Nvidia, Broadcom, Progressive, Draftkings, Moody's...	07-01
Boots CEO Sebastian James to stand down	07-01	AN
Boots CEO James quits after Walgreens' plans for sale stalls, Sky News reporter says	06-29	RE

Chart Walgreens Boots Alliance, Inc.

Duration

Period

More charts

Company Profile

Walgreens Boots Alliance, Inc. specializes in the distribution of pharmaceutical products. Net sales break down by activity as follows: - retail distribution (87.2%): selling prescription drugs, OTC medicines, beauty and cosmetic products, etc. in the United States (90.9% of net sales) and internationally (9.1%). At the end of August 2023, the activity is carried out through 13,532 outlets (of which 8,706 located in the United States, Puerto Rico and the US Virgin Islands), and through the Internet; - wholesale distribution (8.1%). The remaining sales (4.7%) are from the healthcare Net sales break down geographically as follows: the United States (84%), Germany (8.1%), the United Kingdom (6.5%) and other (1.4%).

Sector

Drug Retailers

Calendar

2024-10-09 - Q4 2024 Earnings Release (Projected)

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Walgreens CEO on Narrowed Forecast, Shoppers Cutting Back Spending

March 28, 2024 at 03:59 pm

Walgreens Boots Alliance, Inc. first light at the end of the tunnel?

November 27, 2023 at 10:22 am

More Strategies

Ratings for Walgreens Boots Alliance, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

11.26 USD

Average target price

14.12 USD

Spread / Average Target

+25.39%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Drug Retailers

	1st Jan change	Capi.
WALGREENS BOOTS ALLIANCE, INC.	-56.87%	9.72B
JD HEALTH INTERNATIONAL INC.	-45.52%	8.7B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED	-24.76%	6.57B
MATSUKIYOCOCOKARA & CO.	-5.95%	6.09B
CORPORATIVO FRAGUA, S.A.B. DE C.V.	+91.60%	5.11B
NAHDI MEDICAL COMPANY	-3.36%	4.58B
CLICKS GROUP LIMITED	+1.56%	4.32B
YIFENG PHARMACY CHAIN CO., LTD.	-27.53%	4.03B
REDCARE PHARMACY NV	+2.28%	2.96B
WELCIA HOLDINGS CO., LTD.	-20.90%	2.51B

Other Drug Retailers

Walgreens Boots Alliance, Inc.

Equities

WBA

US9314271084

Drug Retailers

Walgreens Boots Alliance Revises Earnings Guidance for the Full Year of Fiscal 2017

EPS Revisions